{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:14:48Z","timestamp":1790234088609,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T00:00:00Z","timestamp":1334188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00415-012-6487-5","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T11:00:28Z","timestamp":1334142028000},"page":"2293-2298","source":"Crossref","is-referenced-by-count":34,"title":["Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy"],"prefix":"10.1007","volume":"259","author":[{"given":"Olivier","family":"Outteryck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Ongagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-C\u00e9line","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Giroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,12]]},"reference":[{"key":"6487_CR1","unstructured":"Sandrock A, Hotermans C, Richman S et al (2011) Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: Role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status [Poster AAN 2011]. P03.248"},{"key":"6487_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","volume":"68","author":"L Gorelik","year":"2010","unstructured":"Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 68:295\u2013303","journal-title":"Ann Neurol"},{"key":"6487_CR3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariate prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361\u2013387","journal-title":"Stat Med"},{"key":"6487_CR4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/sim.4780111607","volume":"11","author":"W Sauerbrei","year":"1992","unstructured":"Sauerbrei W, Schumacher M (1992) A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 11:2093\u20132109","journal-title":"Stat Med"},{"issue":"suppl","key":"6487_CR5","first-page":"P520","volume":"10","author":"C Warnke","year":"2011","unstructured":"Warnke C, Dehmel T, Posevitz-Fejf\u00e0r A et al (2011) Anti-JCV antibody prevalence in a german MS cohort [abstract]. Mult Scler 10(suppl):P520","journal-title":"Mult Scler"},{"issue":"suppl","key":"6487_CR6","first-page":"P338","volume":"10","author":"T Olsson","year":"2011","unstructured":"Olsson T, Achiron A, Alfredsson L et al (2011) Prevalence of anti JCV antibodies in a multi-national cohort of multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P338","journal-title":"Mult Scler"},{"key":"6487_CR7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T et al (2011) Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 70:742\u2013750","journal-title":"Ann Neurol"},{"key":"6487_CR8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/597126","volume":"199","author":"A Egli","year":"2009","unstructured":"Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:836\u2013846","journal-title":"J Infect Dis"},{"key":"6487_CR9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067\u20131074","journal-title":"N Engl J Med"},{"key":"6487_CR10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","volume":"68","author":"RA Rudick","year":"2009","unstructured":"Rudick RA, O\u2019Connor PW, Polman CH et al (2009) Assessment of JC Virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304\u2013310","journal-title":"Ann Neurol"},{"issue":"suppl","key":"6487_CR11","first-page":"P801","volume":"10","author":"C Bozic","year":"2011","unstructured":"Bozic C, Subramanyam M, Paes D et al (2011) JCV epidemiology in MS: epidemiology on anti-JC virus antibody prevalence in multiple sclerosis patients [abstract]. Mult Scler 10(suppl):P801","journal-title":"Mult Scler"},{"key":"6487_CR12","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697\u20131704","journal-title":"Neurology"},{"key":"6487_CR13","first-page":"284","volume":"83","author":"R Phan-Ba","year":"2011","unstructured":"Phan-Ba R, Lommers E, Tshibanda L (2011) MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 83:284\u2013286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6487_CR14","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","volume":"10","author":"L Kappos","year":"2011","unstructured":"Kappos L, Bates D, Edan G et al (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745\u2013758","journal-title":"Lancet Neurol"},{"key":"6487_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","volume":"18","author":"PS Sorensen","year":"2012","unstructured":"Sorensen PS, Bertolotto A, Edan G et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mutl Scler 18:143\u2013152","journal-title":"Mutl Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-012-6487-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-012-6487-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:23:02Z","timestamp":1559056982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-012-6487-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,12]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["6487"],"URL":"https:\/\/doi.org\/10.1007\/s00415-012-6487-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,12]]}}}